Advertisement

Applied Biochemistry and Biotechnology

, Volume 187, Issue 4, pp 1328–1343 | Cite as

Synergistic Anticancer Effect of a Combination of Paclitaxel and 5-Demethylnobiletin Against Lung Cancer Cell Line In Vitro and In Vivo

  • Kok-Tong Tan
  • Shiming Li
  • Yi Rong Li
  • Shih-Lung Cheng
  • Sheng-Hao LinEmail author
  • Yu-Tang TungEmail author
Article

Abstract

Lung cancer remains a highly prevalent disease and a leading cause of cancer-related deaths worldwide. Currently, exploring antitumor drugs derived from herbs used in traditional Chinese medicine is increasingly becoming an attractive area of research. Paclitaxel (PTX), a highly effective chemotherapeutic drug, is widely used for treating different cancers; however, the clinical use of PTX is dose limited because of its adverse side effects. Chemotherapeutic agents are being developed to enhance the anticancer activity of PTX, particularly for use in combination therapy. 5-Demethylnobiletin (5-DMN), a natural, active compound isolated from orange peel, has been reported to induce apoptosis in several cancer cell lines. In this study, we tested the synergistic anticancer antiproliferative effects of combinations of PTX and 5-DMN on CL1–5 lung cancer cells through the MTT and propidium iodide assays. After low-dose combination treatments (PTX and 5-DMN), a reduction in cell viability and a concomitant increase in apoptosis were observed in the CL1–5 cells. We propose that 5-DMN cooperates with PTX to induce apoptosis via the caspase pathway (by modulating caspase-3, caspase-8, and caspase-9 activities). Furthermore, we observed that the combination treatment significantly suppressed tumor growth in the nude mouse xenograft model. The results suggest that the synergistic effects of PTX and 5-DMN in lung cancer cells deserve particular attention and indicate the possibility of developing additional new strategies for treating lung cancer.

Keywords

Paclitaxel 5-Demethylnobiletin Non-small cell lung cancer Apoptosis Synergistic effect 

Notes

Funding

This study was supported by grants (106-CCH-IRP-072) from Changhua Christian Hospital, Taiwan.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., Cortinovis, D. L., Leach, J., Polikoff, J., Barrios, C., Kabbinavar, F., Frontera, O. A., De Marinis, F., Turna, H., Lee, J. S., Ballinger, M., Kowanetz, M., He, P., Chen, D. S., Sandler, A., Gandara, D. R., & OAK Study Group. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 389(10066), 255–265.CrossRefGoogle Scholar
  2. 2.
    Li, C. J., Chu, C. Y., Huang, L. H., Wang, M. H., Sheu, L. F., Yeh, J. I., & Hsu, H. Y. (2012). Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo. Cancer Letters, 319(2), 203–213.CrossRefGoogle Scholar
  3. 3.
    Yuan, H., Sun, B., Gao, F., & Lan, M. (2016). Synergistic anticancer effects of andrographolide and paclitaxel against A549 NSCLC cells. Pharmaceutical Biology, 54(11), 2629–2635.CrossRefGoogle Scholar
  4. 4.
    Koch, G., Walz, A., Lahu, G., & Schropp, J. (2009). Modeling of tumor growth and anticancer effects of combination therapy. Journal of Pharmacokinetics and Pharmacodynamics, 36(2), 179–187.CrossRefGoogle Scholar
  5. 5.
    Rocchetti, M., Bene, F. D., Germani, M., Fiorentini, F., Poggesi, I., Pesenti, E., Magni, P., & De Nicolao, G. (2009). Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach. European Journal of Cancer, 45(18), 3336–3346.CrossRefGoogle Scholar
  6. 6.
    Schicher, N., Paulitschke, V., Swoboda, A., Kunstfeld, R., Loewe, R., Pilarski, P., Pehamberger, H., & Hoeller, C. (2009). Erlotinib and bevacizumab have synergistic activity against melanoma. Clinical Cancer Research, 15(10), 3495–3502.CrossRefGoogle Scholar
  7. 7.
    Goteti, K., Garner, C., Utley, L., Dai, J., Ashwell, S., Moustakas, D. T., Gönen, M., Schwartz, G. K., Kern, S. E., Zabludoff, S., & Brassil, P. J. (2010). Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents. Cancer Chemotherapy and Pharmacology, 66(2), 245–254.CrossRefGoogle Scholar
  8. 8.
    Nikolic, V. D., Savic, I. M., Savic, I. M., Nikolic, L. B., Stankovic, M. Z., & Marinkovic, V. D. (2011). Paclitaxel as an anticancer agent: isolation, activity, synthesis and stability. Central European Journal of Medicine, 6, 527–536.Google Scholar
  9. 9.
    Asik, A., Kayabasi, C., Ozmen Yelken, B., Yılmaz Susluer, S., Dogan Sigva, Z. O., Balcı Okcanoglu, T., Saydam, G., Biray Avci, C., & Gunduz, C. (2018). Antileukemic effect of paclitaxel in combination with metformin in HL-60 cell line. Gene, S0378–1119, 30024–30026.Google Scholar
  10. 10.
    Li, S., Lambros, T., Wang, Z., Goodnow, R., & Ho, C. T. (2007). Efficient and scalable method in isolation of polymethoxyflavones from orange peel extract by supercritical fluid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 846(1-2), 291–297.CrossRefGoogle Scholar
  11. 11.
    Li, F., Zhao, C., & Wang, L. (2014). Molecular-targeted agents combination therapy for cancer: Developments and potentials. International Journal of Cancer, 134(6), 1257–1269.CrossRefGoogle Scholar
  12. 12.
    Chen, Y. K., Wang, H. C., Ho, C. T., Chen, H. Y., Li, S., Chan, H. L., Chung, T. W., Tan, K. T., Li, Y. R., & Lin, C. C. (2015). 5-demethylnobiletin promotes the formation of polymerized tubulin, leads to G2/M phase arrest and induces autophagy via JNK activation in human lung cancer cells. The Journal of Nutritional Biochemistry, 26(5), 484–504.CrossRefGoogle Scholar
  13. 13.
    Li, S., Pan, M. H., Lai, C. S., Lo, C. Y., Dushenkov, S., & Ho, C. T. (2007). Isolation and syntheses of polymethoxyflavones and hydroxylated polymethoxyflavones as inhibitors of HL-60 cell lines. Bioorganic & Medicinal Chemistry, 15(10), 3381–3389.CrossRefGoogle Scholar
  14. 14.
    Xiao, H., Yang, C. S., Li, S., Jin, H., Ho, C. T., & Patel, T. (2009). Monodemethylated polymethoxyflavones from sweet orange (Citrus sinensis) peel inhibit growth of human lung cancer cells by apoptosis. Molecular Nutrition & Food Research, 53(3), 398–406.CrossRefGoogle Scholar
  15. 15.
    Qiu, P., Dong, P., Guan, H., Li, S., Ho, C. T., Pan, M. H., McClements, D. J., & Xiao, H. (2010). Inhibitory effects of 5-hydroxy polymethoxyflavones on colon cancer cells. Molecular Nutrition & Food Research, 54(S2), S244–S252.CrossRefGoogle Scholar
  16. 16.
    Chu, Y. W., Yang, P. C., Yang, S. C., Shyu, Y. C., Hendrix, M. J., Wu, R., & Wu, C. W. (1997). Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. American Journal of Respiratory Cell and Molecular Biology, 17(3), 353–360.CrossRefGoogle Scholar
  17. 17.
    Kodate, M., Kasai, T., Hashimoto, H., Yasumoto, K., Iwata, Y., & Manabe, H. (1997). Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathology International, 47(7), 461–469.CrossRefGoogle Scholar
  18. 18.
    Chou, T. C., & Talalay, P. (1984). Quantitiative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27–55.CrossRefGoogle Scholar
  19. 19.
    Chou, T. C., & Martin, N. (2005). A computer program for quantitation of synergism and antagonism in drug combinations, and the determination of IC50 and ED50 and LD50 values. ComboSyn; Paramus, NJ. CompuSyn for drug combinations: PC software and user’s guide.Google Scholar
  20. 20.
    Chou, T. C. (1991). The median-effect principle and combination index for quantitation of synergism and antagonism. In T. C. Chou & D. C. Rideout (Eds.), Synergism and antagonism in chemotherapy (pp. 61–102). San Diego: Academic Press.Google Scholar
  21. 21.
    Chou, T. C., Motzer, R. J., Tong, Y., & Bosl, G. J. (1994). Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. Journal of the National Cancer Institute, 86(20), 1517–1524.CrossRefGoogle Scholar
  22. 22.
    Weaver, B. A. (2014). How Taxol/paclitaxel kills cancer cells. Molecular Biology of the Cell, 25(18), 2677–2681.CrossRefGoogle Scholar
  23. 23.
    Hanna, R. K., Zhou, C., Malloy, K. M., Sun, L., Zhong, Y., Gehrig, P. A., & Bae-Jump, V. L. (2012). Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecologic Oncology, 125(2), 458–469.CrossRefGoogle Scholar
  24. 24.
    Frances, N., Claret, L., Bruno, R., & Iliadis, A. (2011). Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 68(6), 1413–1419.CrossRefGoogle Scholar
  25. 25.
    Liu, K., Cang, S., Ma, Y., & Chiao, J. W. (2013). Synergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cells. Cancer Cell International, 13(1), 10.CrossRefGoogle Scholar
  26. 26.
    Alexandre, J., Batteux, F., Nicco, C., Chéreau, C., Laurent, A., Guillevin, L., Weill, B., & Goldwasser, F. (2006). Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. International Journal of Cancer, 119(1), 41–48.CrossRefGoogle Scholar
  27. 27.
    Wang, L., Liu, X., Wu, Y., Wu, W., & Wu, Y. (2012). Involvement of ROS in the inhibitory effect of thermotherapy combined with chemotherapy on A549 human lung adenocarcinoma cell growth through the Akt pathway. Oncology Reports, 28(4), 1369–1375.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of SurgeryTungs’ Taichung MetroHarbor HospitalTaichungRepublic of China
  2. 2.Institute of Biomedical ScienceNational Chung-Hsing UniversityTaichungRepublic of China
  3. 3.Department of Food ScienceRutgers UniversityNew BrunswickUSA
  4. 4.Department of Internal MedicineFar Eastern Memorial HospitalTaipeiRepublic of China
  5. 5.Department of Chemical Engineering and Materials ScienceYuan Ze UniversityTaoyuanRepublic of China
  6. 6.Division of Chest Medicine, Department of Internal MedicineChanghua Christian HospitalChanghuaRepublic of China
  7. 7.Graduate Institute of Metabolism and Obesity SciencesTaipei Medical UniversityTaipeiRepublic of China

Personalised recommendations